메뉴 건너뛰기




Volumn 79, Issue 5, 2015, Pages 744-755

Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects

Author keywords

chromogranin A; gastric acid; gastrin CCK2 receptor antagonist; hypergastrinaemia; netazepide; rabeprazole

Indexed keywords

CHOLECYSTOKININ B RECEPTOR ANTAGONIST; CHROMOGRANIN A; GASTRIN; GAVISCON; NETAZEPIDE; PENTAGASTRIN; RABEPRAZOLE; BENZODIAZEPINE DERIVATIVE; CARBANILAMIDE DERIVATIVE; CHOLECYSTOKININ B RECEPTOR;

EID: 84928345650     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12534     Document Type: Article
Times cited : (19)

References (43)
  • 1
    • 0035043972 scopus 로고    scopus 로고
    • The gastrins: Their production and biological activities
    • Dockray GJ, Varro A, Dimaline R, Wang T,. The gastrins: their production and biological activities. Annu Rev Physiol 2001; 63: 119-139.
    • (2001) Annu Rev Physiol , vol.63 , pp. 119-139
    • Dockray, G.J.1    Varro, A.2    Dimaline, R.3    Wang, T.4
  • 2
    • 34347373469 scopus 로고    scopus 로고
    • Attack and defence in the gastric epithelium - A delicate balance
    • Dimaline R, Varro A,. Attack and defence in the gastric epithelium-a delicate balance. Exp Physiol 2007; 92: 591-601.
    • (2007) Exp Physiol , vol.92 , pp. 591-601
    • Dimaline, R.1    Varro, A.2
  • 3
    • 44649104570 scopus 로고    scopus 로고
    • Control of gastric acid secretion in health and disease
    • Schubert ML, Peura DA,. Control of gastric acid secretion in health and disease. Gastroenterology 2008; 134: 1842-1860.
    • (2008) Gastroenterology , vol.134 , pp. 1842-1860
    • Schubert, M.L.1    Peura, D.A.2
  • 4
    • 0034960085 scopus 로고    scopus 로고
    • Effect of long-term, continuous versus alternate-day omeprazole therapy on serum gastrin in patients treated for reflux esophagitis
    • Ligumsky M, Lysy J, Siguencia G, Friedlander Y,. Effect of long-term, continuous versus alternate-day omeprazole therapy on serum gastrin in patients treated for reflux esophagitis. J Clin Gastroenterol 2001; 33: 32-35.
    • (2001) J Clin Gastroenterol , vol.33 , pp. 32-35
    • Ligumsky, M.1    Lysy, J.2    Siguencia, G.3    Friedlander, Y.4
  • 5
    • 17844368379 scopus 로고    scopus 로고
    • Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa
    • European Rabeprazole Study Group
    • Rindi G, Fiocca R, Morocutti A, Jacobs A, Miller N, Thjodleifsson B, European Rabeprazole Study Group. Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. Eur J Gastroenterol Hepatol 2005; 17: 559-566.
    • (2005) Eur J Gastroenterol Hepatol , vol.17 , pp. 559-566
    • Rindi, G.1    Fiocca, R.2    Morocutti, A.3    Jacobs, A.4    Miller, N.5    Thjodleifsson, B.6
  • 6
    • 0033958779 scopus 로고    scopus 로고
    • Treatment with lansoprazole also induces hypertrophy of the parietal cells of the stomach
    • Stolte M, Meining A, Seifert E, Alexandridis T,. Treatment with lansoprazole also induces hypertrophy of the parietal cells of the stomach. Pathol Res Pract 2000; 196: 9-13.
    • (2000) Pathol Res Pract , vol.196 , pp. 9-13
    • Stolte, M.1    Meining, A.2    Seifert, E.3    Alexandridis, T.4
  • 7
    • 0030468499 scopus 로고    scopus 로고
    • Marked increase in gastric acid secretory capacity after omeprazole treatment
    • Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen U, Sandvik AK,. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 1996; 39: 649-653.
    • (1996) Gut , vol.39 , pp. 649-653
    • Waldum, H.L.1    Arnestad, J.S.2    Brenna, E.3    Eide, I.4    Syversen, U.5    Sandvik, A.K.6
  • 8
    • 0032924619 scopus 로고    scopus 로고
    • Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status
    • Gillen D, Wirz AA, Ardill JE, McColl KE,. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 1999; 116: 239-247.
    • (1999) Gastroenterology , vol.116 , pp. 239-247
    • Gillen, D.1    Wirz, A.A.2    Ardill, J.E.3    McColl, K.E.4
  • 9
    • 67649222366 scopus 로고    scopus 로고
    • Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy
    • Reimer C, Sondergaard B, Hilsted L, Bytzer P,. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009; 137: 80-87.
    • (2009) Gastroenterology , vol.137 , pp. 80-87
    • Reimer, C.1    Sondergaard, B.2    Hilsted, L.3    Bytzer, P.4
  • 10
    • 77954424083 scopus 로고    scopus 로고
    • Dyspeptic symptom development after discontinuation of a proton pump inhibitor: A double-blind placebo-controlled trial
    • Niklasson A, Lindstrom L, Simren M, Lindberg G, Bjornsson E,. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol 2010; 105: 1531-1537.
    • (2010) Am J Gastroenterol , vol.105 , pp. 1531-1537
    • Niklasson, A.1    Lindstrom, L.2    Simren, M.3    Lindberg, G.4    Bjornsson, E.5
  • 11
    • 33750000586 scopus 로고    scopus 로고
    • Pathogenesis and management of gastric carcinoid tumours
    • Burkitt MD, Pritchard DM,. Pathogenesis and management of gastric carcinoid tumours. Aliment Pharmacol Ther 2006; 24: 1305-1320.
    • (2006) Aliment Pharmacol Ther , vol.24 , pp. 1305-1320
    • Burkitt, M.D.1    Pritchard, D.M.2
  • 13
    • 0041919640 scopus 로고    scopus 로고
    • Cholecystokinin antagonists: Pharmacological and therapeutic potential
    • Herranz R,. Cholecystokinin antagonists: pharmacological and therapeutic potential. Med Res Rev 2003; 23: 559-605.
    • (2003) Med Res Rev , vol.23 , pp. 559-605
    • Herranz, R.1
  • 14
    • 14444288026 scopus 로고    scopus 로고
    • (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): A potent and orally active gastrin/CCK-B antagonist
    • Semple G, Ryder H, Rooker DP, Batt AR, Kendrick DA, Szelke M, Ohta M, Satoh M, Nishida A, Akuzawa S, Miyata K,. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist. J Med Chem 1997; 40: 331-341.
    • (1997) J Med Chem , vol.40 , pp. 331-341
    • Semple, G.1    Ryder, H.2    Rooker, D.P.3    Batt, A.R.4    Kendrick, D.A.5    Szelke, M.6    Ohta, M.7    Satoh, M.8    Nishida, A.9    Akuzawa, S.10    Miyata, K.11
  • 17
    • 0034073187 scopus 로고    scopus 로고
    • Long-lasting cholecystokinin(2) receptor blockade after a single subcutaneous injection of YF476 or YM022
    • Kitano M, Norlén P, Ding XQ, Nakamura S, Håkanson R,. Long-lasting cholecystokinin(2) receptor blockade after a single subcutaneous injection of YF476 or YM022. Br J Pharmacol 2000; 130: 699-705.
    • (2000) Br J Pharmacol , vol.130 , pp. 699-705
    • Kitano, M.1    Norlén, P.2    Ding, X.Q.3    Nakamura, S.4    Håkanson, R.5
  • 18
    • 0033962308 scopus 로고    scopus 로고
    • Effect of cholecystokinin-2 receptor blockade on rat stomach ECL cells. A histochemical, electron-microscopic and chemical study
    • Chen D, Zhao CM, Norlén P, Björkqvist M, Ding XQ, Kitano M, Håkanson R,. Effect of cholecystokinin-2 receptor blockade on rat stomach ECL cells. A histochemical, electron-microscopic and chemical study. Cell Tissue Res 2000; 299: 81-95.
    • (2000) Cell Tissue Res , vol.299 , pp. 81-95
    • Chen, D.1    Zhao, C.M.2    Norlén, P.3    Björkqvist, M.4    Ding, X.Q.5    Kitano, M.6    Håkanson, R.7
  • 20
  • 21
    • 0030725409 scopus 로고    scopus 로고
    • Evaluation of three novel cholecystokinin-B/gastrin receptor antagonists: A study of their effects on rat stomach enterochromaffin-like cell activity
    • Ding XQ, Lindström E, Håkanson R,. Evaluation of three novel cholecystokinin-B/gastrin receptor antagonists: a study of their effects on rat stomach enterochromaffin-like cell activity. Pharmacol Toxicol 1997; 81: 232-237.
    • (1997) Pharmacol Toxicol , vol.81 , pp. 232-237
    • Ding, X.Q.1    Lindström, E.2    Håkanson, R.3
  • 22
    • 0034993548 scopus 로고    scopus 로고
    • Mobilization of rat stomach ECL-cell histamine in response to short- or long-term treatment with omeprazole and/or YF 476 studied by gastric submucosal microdialysis in conscious rats
    • Konagaya T, Bernsand M, Norlén P, Håkanson R,. Mobilization of rat stomach ECL-cell histamine in response to short- or long-term treatment with omeprazole and/or YF 476 studied by gastric submucosal microdialysis in conscious rats. Br J Pharmacol 2001; 133: 37-42.
    • (2001) Br J Pharmacol , vol.133 , pp. 37-42
    • Konagaya, T.1    Bernsand, M.2    Norlén, P.3    Håkanson, R.4
  • 25
    • 84862578459 scopus 로고    scopus 로고
    • Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects
    • Boyce M, David O, Darwin K, Mitchell T, Johnston A, Warrington S,. Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects. Aliment Pharmacol Ther 2012; 36: 181-189.
    • (2012) Aliment Pharmacol Ther , vol.36 , pp. 181-189
    • Boyce, M.1    David, O.2    Darwin, K.3    Mitchell, T.4    Johnston, A.5    Warrington, S.6
  • 26
    • 84885044301 scopus 로고    scopus 로고
    • Effect of repeated doses of netazepide, a gastrin receptor antagonist, omeprazole and placebo on 24h gastric acidity and gastrin in healthy subjects
    • Boyce M, Warrington S,. Effect of repeated doses of netazepide, a gastrin receptor antagonist, omeprazole and placebo on 24h gastric acidity and gastrin in healthy subjects. Br J Clin Pharmacol 2013; 76: 680-688.
    • (2013) Br J Clin Pharmacol , vol.76 , pp. 680-688
    • Boyce, M.1    Warrington, S.2
  • 27
    • 84885085678 scopus 로고    scopus 로고
    • Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects
    • Boyce M, Warrington S, Black J,. Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects. Br J Clin Pharmacol 2013; 76: 689-698.
    • (2013) Br J Clin Pharmacol , vol.76 , pp. 689-698
    • Boyce, M.1    Warrington, S.2    Black, J.3
  • 28
    • 13844297660 scopus 로고    scopus 로고
    • Patient reported outcomes in gastroesophageal reflux disease: An overview of available measures
    • Talley NJ, Wiklund I,. Patient reported outcomes in gastroesophageal reflux disease: an overview of available measures. Qual Life Res 2005; 14: 21-33.
    • (2005) Qual Life Res , vol.14 , pp. 21-33
    • Talley, N.J.1    Wiklund, I.2
  • 29
    • 0037024133 scopus 로고    scopus 로고
    • Validation of a liquid chromatographic-tandem mass spectrometric method for the measurement of (R)-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl]-3-(3-methylaminophenyl)urea (YF476) in human plasma
    • Redrup MJ, Leaf FC, Miyashita A, Watanabe T, Higuchi S, Chasseaud LF, Cheng KN,. Validation of a liquid chromatographic-tandem mass spectrometric method for the measurement of (R)-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl]-3-(3-methylaminophenyl)urea (YF476) in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 772: 317-325.
    • (2002) J Chromatogr B Analyt Technol Biomed Life Sci , vol.772 , pp. 317-325
    • Redrup, M.J.1    Leaf, F.C.2    Miyashita, A.3    Watanabe, T.4    Higuchi, S.5    Chasseaud, L.F.6    Cheng, K.N.7
  • 32
    • 78049498837 scopus 로고    scopus 로고
    • A meal test improves the specificity of chromogranin A as a marker of neuroendocrine neoplasia
    • Jianu CS, Fossmark R, Syversen U, Hauso O, Waldum HL,. A meal test improves the specificity of chromogranin A as a marker of neuroendocrine neoplasia. Tumour Biol 2010; 31: 373-380.
    • (2010) Tumour Biol , vol.31 , pp. 373-380
    • Jianu, C.S.1    Fossmark, R.2    Syversen, U.3    Hauso, O.4    Waldum, H.L.5
  • 33
    • 84861829850 scopus 로고    scopus 로고
    • Long-term, open-label trial: Safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease
    • Brunner G, Athmann C, Schneider A,. Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Aliment Pharmacol Ther 2012; 36: 37-47.
    • (2012) Aliment Pharmacol Ther , vol.36 , pp. 37-47
    • Brunner, G.1    Athmann, C.2    Schneider, A.3
  • 34
    • 0027200573 scopus 로고
    • Time-dependent changes in enterochromaffin-like cell kinetics in stomach of hypergastrinemic rats
    • Håkanson R, Tielemans Y, Chen D, Andersson K, Mattsson H, Sundler F,. Time-dependent changes in enterochromaffin-like cell kinetics in stomach of hypergastrinemic rats. Gastroenterology 1993; 105: 15-21.
    • (1993) Gastroenterology , vol.105 , pp. 15-21
    • Håkanson, R.1    Tielemans, Y.2    Chen, D.3    Andersson, K.4    Mattsson, H.5    Sundler, F.6
  • 36
    • 0033388447 scopus 로고    scopus 로고
    • Clinical and histopathological tumour progression in ECL cell carcinoids
    • Qvigstad G, Falkmer S, Westre B, Waldum HL,. Clinical and histopathological tumour progression in ECL cell carcinoids. APMIS 1999; 107: 1085-1092.
    • (1999) APMIS , vol.107 , pp. 1085-1092
    • Qvigstad, G.1    Falkmer, S.2    Westre, B.3    Waldum, H.L.4
  • 37
    • 33845388064 scopus 로고    scopus 로고
    • Systematic review: Rebound acid hypersecretion after therapy with proton pump inhibitors
    • Hunfeld NG, Geus WP, Kuipers EJ,. Systematic review: rebound acid hypersecretion after therapy with proton pump inhibitors. Aliment Pharmacol Ther 2007; 25: 39-46.
    • (2007) Aliment Pharmacol Ther , vol.25 , pp. 39-46
    • Hunfeld, N.G.1    Geus, W.P.2    Kuipers, E.J.3
  • 38
    • 0033995574 scopus 로고    scopus 로고
    • Does fasting serum gastrin predict gastric acid suppression in patients on proton-pump inhibitors?
    • Bonapace ES, Fisher RS, Parkman HP,. Does fasting serum gastrin predict gastric acid suppression in patients on proton-pump inhibitors? Dig Dis Sci 2000; 45: 34-39.
    • (2000) Dig Dis Sci , vol.45 , pp. 34-39
    • Bonapace, E.S.1    Fisher, R.S.2    Parkman, H.P.3
  • 40
    • 0032771540 scopus 로고    scopus 로고
    • Review article: The pharmacokinetics of rabeprazole in health and disease
    • Swan SK, Hoyumpa AM, Merritt GJ,. Review article: the pharmacokinetics of rabeprazole in health and disease. Aliment Pharmacol Ther 1999; 13: (Suppl. 3): 11-17.
    • (1999) Aliment Pharmacol Ther , vol.13 , pp. 11-17
    • Swan, S.K.1    Hoyumpa, A.M.2    Merritt, G.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.